Effects of two novel nucleoside analogues on different hepatitis B virus promoters

Table 3 Effect-dosage relationship of the inhibition of the expression of EGFP under the control of the Cp and Xp promoters by β-LPA

Dosage (&mgr;mol/L)	n	EGFP-positive cells (%) (mean ± SD)		Inhibition rate (%)
		Cp	Xp	Cp	Xp
Control	3	13.99 ± 0.29	18.58 ± 0.39	0.0	0.0
(Lamivudine)	4	13.80 ± 0.63	18.46 ± 0.49	1.3	0.6
0.002	4	12.98 ± 0.16b	17.54 ± 0.31b	7.2	5.6
0.01	4	11.96 ± 0.75b	16.18 ± 0.21b	14.5	12.9
0.05	4	10.88 ± 0.43b	14.63 ± 0.37b	22.2	21.3
1	4	8.79 ± 0.56b	11.94 ± 1.37b	37.7	35.7

^bP < 0.01 vs Blank control. EGFP: Enhanced green fluorescent protein.